- Home
- ANTX vs WHWK Comparison
ANTX vs WHWK Comparison
Compare ANTX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | WHWK |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 187.4M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANTX | WHWK |
|---|---|---|
| Price | $5.83 | $4.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $7.50 |
| AVG Volume (30 Days) | 196.2K | ★ 431.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.56 | ★ 86.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $1.60 |
| 52 Week High | $7.19 | $5.50 |
Technical Indicators
Market Signals| Indicator | ANTX | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 63.64 |
| Support Level | $3.91 | $3.79 |
| Resistance Level | $6.91 | $4.84 |
| Average True Range (ATR) | 0.49 | 0.30 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 38.43 | 90.40 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.